CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
Intest Res. 2019;17(3):375-386.   Published online February 12, 2019
DOI: https://doi.org/10.5217/ir.2018.00141

Excel Download

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Intestinal Research. 2019;17(3):375-386   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of Abrilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study
Gastroenterology. 2017;152(5):S198   Crossref logo
Link1 Link2

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
Journal of Gastroenterology. 2017;52(10):1101-1111   Crossref logo
Link1 Link2 Link3

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre randomized, vehicle-controlled clinical study
British Journal of Dermatology. 2018;178(2):e169-e169   Crossref logo
Link1 Link2

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
British Journal of Dermatology. 2018;178(2):424-432   Crossref logo
Link1 Link2

882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study
Gastroenterology. 2018;154(6):S-1360-S-1361   Crossref logo
Link1 Link2

The Efficacy of Vedolizumab, an α4β7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis
Intestinal Research. 2013;11(4):325   Crossref logo
Link1

Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin
Yearbook of Gastroenterology. 2006;2006:137-138   Crossref logo
Link1 Link2

Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin
Yearbook of Pediatrics. 2007;2007:168-170   Crossref logo
Link1 Link2

Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
Intestinal Research. 2019;17(3):283-284   Crossref logo
Link1 Link2 Link3